Gotham Asset Management LLC Sells 24,032 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Gotham Asset Management LLC decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 46.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,074 shares of the specialty pharmaceutical company's stock after selling 24,032 shares during the quarter. Gotham Asset Management LLC owned about 0.09% of Collegium Pharmaceutical worth $804,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in COLL. Barclays PLC increased its holdings in Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after buying an additional 45,291 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Collegium Pharmaceutical by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,620 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Collegium Pharmaceutical by 4.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 75,095 shares of the specialty pharmaceutical company's stock valued at $2,151,000 after purchasing an additional 3,402 shares during the period. Finally, KBC Group NV raised its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after purchasing an additional 982 shares during the period.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares of the company's stock, valued at $4,928,070. The trade was a 0.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,693 shares of company stock worth $2,334,994. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Trading Up 3.0%

Shares of NASDAQ:COLL opened at $30.23 on Monday. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The business has a 50 day moving average of $28.12 and a 200-day moving average of $29.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market cap of $971.35 million, a PE ratio of 13.03 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same period in the previous year, the business posted $1.45 earnings per share. The business's revenue for the quarter was up 22.7% on a year-over-year basis. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Wall Street Analyst Weigh In

COLL has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler reissued a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.